Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | RHOA | P61586 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4396126 | 0.87 | CYP3A4 (0.42) | CYP3A4TSHRALDH1A1HSD17B10MAPT | |
| SCHEMBL7095889 | 0.82 | CYP3A4 (0.45) | CYP3A4TSHRALDH1A1HSD17B10MAPT | |
| SCHEMBL8207148 | 0.82 | CYP3A4 (0.41) | CYP3A4TSHRALDH1A1HSD17B10MAPT | |
| SCHEMBL1082749 | 0.82 | CYP3A4 (0.41) | CYP3A4TSHRALDH1A1HSD17B10MAPT | |
| SCHEMBL11444238 | 0.80 | CYP3A4 (0.39) | CYP3A4TSHRALDH1A1HSD17B10MAPT | |
| SCHEMBL29506833 | 0.80 | CYP3A4 (0.39) | CYP3A4TSHRALDH1A1HSD17B10MAPT | |
| Ammonia Solution, Strong SCHEMBL11233126 | 0.80 | CYP3A4 (0.39) | CYP3A4TSHRALDH1A1HSD17B10MAPT | |
| SCHEMBL28761387 | 0.80 | CYP3A4 (0.39) | CYP3A4TSHRALDH1A1HSD17B10MAPT | |
| SCHEMBL28427366 | 0.80 | CYP3A4 (0.39) | CYP3A4TSHRALDH1A1HSD17B10MAPT | |
| SCHEMBL8586425 | 0.78 | CYP3A4 (0.38) | CYP3A4TSHRALDH1A1HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107001278-B | Tetrahydroisoquinoline derivatives | UCB生物制药私人有限公司 | 2020-11-24 | — | — | CN | disclosed |
| EP-3204359-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2020-07-01 | — | — | EP | disclosed |
| US-10105359-B2 | Tetrahydroisoquinoline derivatives | UCB BIOPHARMA SPRL (BE) | 2018-10-23 | — | — | US | disclosed |
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-10-26 | — | — | US | disclosed |
| EP-3204359-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB Biopharma SPRL (BE) | 2017-08-16 | — | — | EP | disclosed |
| EP-2714697-B1 | SPIRO-[1,3]-OXAZINES AND SPIRO-[1,4]-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2016-08-31 | — | — | EP | disclosed |
| WO-2016055479-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-04-14 | — | — | WO | disclosed |
| US-9079919-B2 | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-8389513-B2 | 2-amino-5,5-difluoro-5,6-dihydro-4H-[1,3]oxazin-4-yl)-phenyl]-amides | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| WO-2012163790-A1 | SPIRO-[1,3]-OXAZINES AND SPIRO-[1,4]-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-06 | — | — | WO | disclosed |
| EP-0409676-A1 | Novel acetylcholinesterase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-01-23 | — | — | EP | disclosed |
| EP-0403713-A1 | Novel acetylcholinesterase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-12-27 | — | — | EP | disclosed |
| EP-0345428-A1 | Anti-amnesic pyrrolidine derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1989-12-13 | — | — | EP | disclosed |
| US-4808614-A | Difluoro antivirals and intermediate therefor | ELI LILLY AND COMPANY (US) | 1989-02-28 | — | — | US | disclosed |
| EP-0122707-B1 | IMPROVEMENTS IN OR RELATING TO NOVEL DIFLUORO ANTIVIRAL AGENTS | ELI LILLY AND COMPANY (US) | 1987-09-16 | — | — | EP | disclosed |
| US-4692434-A | NUCLEOSIDES | ELI LILLY AND COMPANY (US) | 1987-09-08 | — | — | US | disclosed |
| EP-0211354-A2 | Nucleosides and their use as antineoplastic agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-02-25 | — | — | EP | disclosed |
| EP-0184365-A2 | Improvements in the treatment of tumors in mammals | ELI LILLY AND COMPANY (US) | 1986-06-11 | — | — | EP | disclosed |
| US-4526988-A | Hydrolyzing alkyl 3-dioxolanyl-2,2-difluoro-3-hydroxy propionate | ELI LILLY AND COMPANY (US) | 1985-07-02 | — | — | US | disclosed |
| EP-0122707-A1 | Improvements in or relating to novel difluoro antiviral agents | ELI LILLY AND COMPANY (US) | 1984-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | OPRD1, ADRA1D, GPR52 | CYP3A4 727/4885TSHR 135/4885ALDH1A1 950/4885 |
| US-10105359-B2 | Tetrahydroisoquinoline derivatives | OPRD1, ADRA1D, GPR52 | CYP3A4 727/4885TSHR 135/4885ALDH1A1 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.